BIO2018, here we come: Real-time oncology and biomarkers for Alzheimer’s disease

The BIO International Convention is a huge gathering each year, as around 15-18,000 representatives from across industry and around the world get together to discuss policy, partnering, and product development over the course of four days. This year’s event, to… Read »

New Contender in Race to Develop Allogeneic CAR-T Treatments

Just months after negotiating the sale of autologous CAR-T pioneer Kite Pharma to Gilead for $11.9 billion, two of the executives who led Kite to success are back with a new company, a clinical-stage asset, and a portfolio of 16… Read »

Update on FDA’s Patient Benefit-Risk Assessment Program

Over the past several years, the U.S. Food and Drug Administration has begun efforts to further incorporate patient perspective on benefits and risks of potential new treatments in their regulatory reviews and to bring additional transparency and communication to the… Read »

FDA Decision on Dexcom Device Changes Playing Field for Continuous Glucose Monitoring

At the end of March, the U.S. Food and Drug Administration approved a new continuous glucose monitor (CGM) system, the Dexcom G6. The new sensor is smaller than current CGM devices, about the size of a quarter. It comes already… Read »

Moving from Exploratory Collaborations to Record-Setting Deals in IO

In early March, we wrote about the collaboration between Bristol-Myers Squibb and Nektar aimed at developing Nektar’s T-cell stimulating molecule NKTR-214 in combination with BMS’s checkpoint inhibitor Opdivo (nivolumab). That deal brought Nektar an eye-opening $1.85 billion in upfront cash… Read »

Apps and Drugs/ Apps as Drugs

In our January post on what we planned to watch for in 2018, we predicted that digital health would come to the foreground of activity this year. And indeed, we are starting to see a lot of buzz around digital… Read »

The Rise of AI in Drug Discovery and Development

“Deep learning” is an advanced machine learning technology that enables the generation of relevant insights from enormous amounts of data. Computers are able to identify complex patterns in data from many disparate sources and generate algorithms to explain them. This… Read »

Chasing Migraine

Migraine is the most prevalent neurological disorder worldwide. It causes not only painful headaches, but can also be associated with nausea, vomiting, light and noise sensitivity, and fatigue. A migraine attack can last from a few hours to several days…. Read »

Artificial Intelligence Making Gains in Health Care

Applications of artificial intelligence (AI) to health care took a major step forward with two noteworthy events in February in the cardiovascular space.   In the first case, the U.S. Food and Drug Administration (FDA) approved the marketing of a… Read »

Alzheimer’s Disease: Continued Clinical Failure and a Potential New Development Pathway

Alzheimer’s disease continues to be a costly and frustrating minefield for drug developers. Most recently, Boehringer Ingelheim halted development of the phosphodiesterase type 9 (PDE9) inhibitor BI 409306 after it failed in phase 2. Merck also ended its trial of verubecestat,… Read »

1 2 3 4 5 12